Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

Antisense technology is beginning to deliver on the broad promise of the technology. Ten
RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double …

Viral infections affecting the liver have had an important impact on humanity, as they have
led to significant morbidity and mortality in patients with acute and chronic infections. Once …

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality.
Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) …

Recent progress in understanding phosphorothioate antisense oligonucleotide (PS-ASO)
interactions with proteins has revealed that proteins play deterministic roles in the …

When coined, the term “antisense” included oligonucleotides of any structure, with any
chemical modification and designed to work through any post-RNA hybridization …

Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the
progression to cirrhosis and hepatocellular carcinoma, which are serious public health …

The currently recommended treatment for chronic hepatitis B virus (HBV) infection achieves
only viral suppression whilst on therapy, but rarely hepatitis B surface antigen (HBsAg) loss …

In diverse viral infections, the production of excess viral particles containing only viral
glycoproteins (subviral particles or SVP) is commonly observed and is a commonly evolved …

Background and Aims RO7062931 is an N‐acetylgalactosamine (GalNAc)‐conjugated
single‐stranded locked nucleic acid oligonucleotide complementary to HBV RNA. GalNAc …